Table 5.
Grade 3 or higher acute and late toxicity in the propensity-matched cohort
| Type of toxicity | CRT (n=150) | NCT (n=150) | p-value |
|---|---|---|---|
| Acute toxicity (grade 3/4) | |||
| Hematologic | |||
| Grade 3 | 17 (11.3) | 18 (12.0) | 0.857 |
| Grade 4 | 1 (0.7) | 5 (3.3) | 0.214 |
| Anorexia/Nausea/Vomiting | 5 (3.3) | 2 (1.3) | 0.448 |
| Mucositis/Odynophagia | 27 (18.0) | 29 (19.3) | 0.767 |
| Dermatitis | 4 (2.7) | 6 (4.0) | 0.750 |
| Xerostomia | 4 (2.7) | 4 (2.7) | > 0.999 |
| Any acute toxicity | 57 (38.0) | 59 (39.3) | 0.813 |
| Late toxicity (grade 3/4) | |||
| Soft tissue fibrosis | 5 (3.3) | 3 (2.0) | 0.723 |
| Radionecrosis/Neuropathy | 2 (1.3) | 1 (0.7) | > 0.999 |
| Xerostomia | 6 (4.0) | 7 (4.7) | 0.777 |
| Ototoxicity | 1 (0.7) | 2 (1.3) | > 0.999 |
| Any late toxicity | 14 (9.3) | 13 (8.7) | 0.840 |
| Grade 5 toxicity | |||
| Radionecrosis/Neuropathy | 0 | 2 (1.3) | 0.498 |
| Neutropenia/Infection | 1 (0.7) | 0 | > 0.999 |
| Not reported | 2 (1.3) | 2 (1.3) | > 0.999 |
| Any grade 5 toxicity | 3 (2.0) | 4 (2.7) | > 0.999 |
Values are presented as number (%). Treatment toxicities were assessed using the National Cancer Institute’s Common Terminology Criteria for Adverse Events (ver. 3.0). CRT, concurrent chemoradiotherapy arm; NCT, neoadjuvant chemotherapy arm.